StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)

Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –

Niagen Bioscience r&d expenses

Research and development expenses are spending on new products and technology.

Niagen Bioscience's R&D Expenses for the twelve months ending Sep 30, 2026 was $6.50M, up 9.5% year over year. For fiscal 2025 it was $6.33M, up 5.2% from the year before. Over ten years it grew 21.7% a year on average. The highest annual figure on record is $6.33M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.33M+5.2%
FY2024Dec 31, 2024$6.02M+21.3%
FY2023Dec 31, 2023$4.96M+2.7%
FY2022Dec 31, 2022$4.83M+25.9%
FY2021Dec 31, 2021$3.83M+12.2%
FY2020Dec 31, 2020$3.42M-22.7%
FY2019Dec 31, 2019$4.42M-19.3%
FY2018Dec 31, 2018$5.48M+36.7%
FY2017Dec 30, 2017$4.01M+58.8%
FY2016Dec 31, 2016$2.52M+182.9%
FY2015Jan 2, 2016$891.60K+73.6%
FY2014Jan 3, 2015$513.67K+283.2%
FY2013Dec 28, 2013$134.04K-5.6%
FY2012Dec 29, 2012$142.00K+46.7%
FY2011Dec 31, 2011$96.79K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.80M+0.1%
Q2 FY2026Jun 30, 2026$1.51M-3.4%
Q1 FY2026Mar 31, 2026$1.48M+17.7%
Q4 FY2025Dec 31, 2025$1.71M+30.0%
Q3 FY2025Sep 30, 2025$1.80M+39.1%
Q2 FY2025Jun 30, 2025$1.57M+19.1%
Q1 FY2025Mar 31, 2025$1.26M-40.0%
Q4 FY2024Dec 31, 2024$1.32M+13.5%
Q3 FY2024Sep 30, 2024$1.29M+3.9%
Q2 FY2024Jun 30, 2024$1.32M-3.6%
Q1 FY2024Mar 31, 2024$2.10M+75.6%
Q4 FY2023Dec 31, 2023$1.16M-9.4%
Q3 FY2023Sep 30, 2023$1.24M+1.4%
Q2 FY2023Jun 30, 2023$1.37M+9.6%
Q1 FY2023Mar 31, 2023$1.19M+10.7%
Q4 FY2022Dec 31, 2022$1.28M+22.4%
Q3 FY2022Sep 30, 2022$1.22M+22.9%
Q2 FY2022Jun 30, 2022$1.25M+24.0%
Q1 FY2022Mar 31, 2022$1.08M+37.0%
Q4 FY2021Dec 31, 2021$1.05M+20.1%
Q3 FY2021Sep 30, 2021$996.00K+18.4%
Q2 FY2021Jun 30, 2021$1.00M+12.2%
Q1 FY2021Mar 31, 2021$787.00K-14.4%
Q4 FY2020Dec 31, 2020$870.00K-23.6%
Q3 FY2020Sep 30, 2020$841.00K-19.4%
Q2 FY2020Jun 30, 2020$895.00K-16.3%
Q1 FY2020Mar 31, 2020$919.00K-21.3%
Q4 FY2019Dec 31, 2019$1.14M-10.7%
Q3 FY2019Sep 30, 2019$1.04M-22.7%
Q2 FY2019Jun 30, 2019$1.07M-24.4%
Q1 FY2019Mar 31, 2019$1.17M-18.8%
Q4 FY2018Dec 31, 2018$1.28M-12.3%
Q3 FY2018Sep 30, 2018$1.35M+29.8%
Q2 FY2018Jun 30, 2018$1.41M+164.7%
Q1 FY2018Mar 31, 2018$1.44M+86.2%
Q4 FY2017Dec 30, 2017$1.45M–
Q3 FY2017Sep 30, 2017$1.04M–
Q4 FY2016Dec 31, 2016$534.17K–
Q3 FY2016Oct 1, 2016$772.80K–

More Niagen Bioscience figures

See a number that looks wrong?